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p193/CUL7 is an E3 ubiquitin ligase initially identified as an SV40 Large T Antigen binding protein. Expression of a dominant interfering
variant of mouse p193/CUL7 (designated 1152stop) conferred resistance to MG132- and etoposide-induced apoptosis in U2OS cells. Immune
precipitation/Western analyses revealed that endogenous p193/CUL7 formed a complex with Parc (a recently identified parkin-like ubiquitin
ligase) and p53. Apoptosis resistance did not result from 1152stop-mediated disruption of the endogenous p193/CUL7 binding partners.
Moreover, 1152stop molecule did not directly bind to endogenous p193/CUL7, Parc or p53. These data suggested a role for p193/CUL7 in the
regulation of apoptosis independently of p53 and Parc activity.
© 2006 Elsevier B.V. All rights reserved.Keywords: E3 ligase; BH-3 only; SV40 T-Antigen1. Introduction
The balance between cell proliferation and apoptosis is
critical for normal development and for the maintenance of
homeostasis in adult organisms. Disruption of this balance has
been implicated in a large number of disease processes, ranging
from autoimmunity and neurodegenerative disorders to cancer.
Although apoptosis can be triggered by many diverse intracel-
lular and extracellular stimuli, once initiated a conserved set of
molecules are recruited for the execution of the cell death
program which is ultimately dependent upon the activation of
the caspase family of cysteine proteases [1,2].
In order to study the interplay between cell proliferation and
apoptosis in myocardium, we have previously generated
transgenic mice that expressed either wild-type or mutant⁎ Corresponding author.
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regulation of cardiomyocyte restricted promoters [3–5]. Bio-
chemical analyses of cardiomyocyte cell lines derived from
these mice identified three prominent T Antigen binding
proteins, namely p53, p107 and p193 [6]. Subsequent studies
revealed that transient expression of p193 (also known as CUL7,
see below) induced apoptosis in NIH-3T3 cells [7]. p193/CUL7-
induced apoptosis was dependent upon the presence of a short
sequence motif with striking homology to the Bcl-2 homology
domain 3, and furthermore was antagonized by co-expression of
Bcl-xL. These data suggested that p193/CUL7 might be a new
member of the BH3 only pro-apoptosis protein family.
Structure–function experiments revealed that introduction of
a stop codon at amino acid residue #1153 of p193/CUL7
resulted in a molecule with apparent dominant interfering
activity [8]. Expression of this molecule, designated 1152stop,
enhanced cell growth in NIH-3T3 cells. A similar phenotype
was observed with expression of a p193/CUL7 anti-sense
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resistant to methyl methanesulfonate-induced apoptosis, an
agent that promotes DNA damage and induces apoptosis via
both p53-dependent and p53-independent pathways [9,10].
Similarly, co-expression of 1152stop and dominant interfering
p53 was sufficient to block adenoviral E1A oncoprotein-
induced apoptosis in embryonic stem cell-derived cardiomyo-
cytes [8]. Collectively, these data suggested that p193/CUL7
might play a role in the regulation of the balance between cell
cycle activity and cell death in cardiomyocytes.
Ubiquitin-mediated proteolysis plays an important role in
many biological processes, including the regulation of apoptosis
[11,12]. Ubiquitination of a protein is dependent upon the
activities of a ubiquitin-activating enzyme (E1), a ubiquitin-
conjugating enzyme (E2) and a multi-protein adaptor protein
complex (E3). The E3 ubiquitin ligase complexes are respon-
sible for directing the E2 activity to specific protein targets.
Polyubiquitinated proteins are then recognized and degraded by
the 26S proteasome [12,13]. Recent studies revealed that p193/
CUL7 shared homology with members of the cullin family,
which are components of E3 ubiquitin ligases [14–16]. More-
over, p193/CUL7 was found to assemble an SCF-ROC1-like E3
ligase complex, consisting of Skp1, p193/CUL7, Fbx29 (also
called Fbw8), and the ROC1 RING finger protein (also called
Rbx1 or Hrt1) [16,17]. Targets of the p193/CUL7 E3 ligase
activity are currently under investigation.
In this report, the effect of dominant interfering 1152stop
expression on MG132- and etoposide-induced apoptosis was
examined. Transgene expression rendered U2OS cells resistant
to both compounds. MG132 and etoposide induce apoptosis
through markedly different mechanisms than MMS. Specifi-
cally, MG132 inhibits the 26S proteasome, leading to p53-
independent apoptosis. Etoposide is a commonly used che-
motherapeutic agent that has been shown to cause G2 cell cycle
arrest, which in turn induces apoptosis largely via a p53-
dependent pathway. In an effort to identify the mechanistic basis
of apoptosis-resistance, immune precipitation (IP)/Western blot
analyses were performed to determine if 1152stop expression
altered the expression and/or binding activities of the
endogenous p193/CUL7 complex. Endogenous p193/CUL7
was observed to complex with Parc (a recently identified
parkin-like ubiquitin ligase) and p53. Expression of 1152stop
did not alter this complex. Moreover, 1152stop molecule did not
bind to either p53 or Parc. These data suggested a role for p193/
CUL7 in the regulation of apoptosis independently of p53
activity.
2. Materials and methods
2.1. Cell culture conditions and generation of stable cell lines
U2OS, MG-63 and SK-N-AS cells (American Type Culture Collection,
Washington, D.C.) were cultured in DMEM containing 10% fetal calf serum and
antibiotics. Clonal U2OS cell lines stably expressing mouse 1152stop-myc
(U2OS-1152stop) or nuclear localized β-galactosidase (U2OS-nLAC cells)
were generated by transfection of expression constructs using Transit reagent
according to the manufacturer's protocol (Mirus, Houston, TX), followed by
G418 selection (300 μg/mL).2.2. MG132 treatment, Etoposide treatment, and apoptosis assay
Cells were treated with 0.25 μM etoposide for 8 h, washed twice with PBS,
and supplemented with fresh DMEM with 10% fetal bovine serum described
previously [18,19]. Cells were treated with the 26S proteasome inhibitor
N-carbobenzoxyl-Leu-Leu-leucinal (MG132, Calbiochem, San Diego, CA) at
10 μM for 24 h as described previously [20]. To quantitate apoptosis, cells were
harvested, stained with FITC-Annexin V and propidium iodide using a
Molecular Probes (Eugene, OR) Apoptosis Assay Kit as per manufacturer's
instructions, and analyzed by flow cytometry. At least three trials were
performed per group for each drug treatment.
2.3. Generation of mouse monoclonal antibodies against p193/CUL7
Sequences encoding p193/CUL7 amino acid residues 805 through 1689
were subcloned into a pGEX bacterial expression vector (Amersham
Biosciences, Piscataway, NJ). Recombinant protein was separated by size on
polyacrylamide gels, and isolated from gel slices via electroporation as
described [21]. Purified protein was submitted to the Custom Hybridoma
Development Service (St. Louis University Health Sciences Center, St. Louis
MO), and two anti-p193/CUL7 monoclonal antibodies (AB13 and AB38), were
generated using standard hybridoma fusion protocols. To identify the p193/
CUL7 epitopes recognized by these antibodies, a nested array of overlapping
13-mer synthetic peptides representing p193/CUL7 amino acid residues 805
through 1689 were spotted onto a nitrocellulose filter (Jerini BiopTools, Berlin,
Germany) and reacted individually with AB13 or AB38. Signal was then
developed using HRP-conjugated anti-mouse antibody and ECL (Amersham
Biosciences, Piscataway, NJ).
2.4. Immune precipitation and Western blot
All immune precipitation reactions were repeated a minimum of three times,
with comparable results. Proteins were extracted directly from tissues or cells
using NP40 buffer as previously described [22,23]. In some experiments, protein
was prepared from p193/CUL7-null mice (H. Nakajima and L.J. Field, in
preparation). Protein content was quantitated using Coomassie Blue method
(Pierce, Rockford, IL). For total protein Western blots, the filters were stained
with 0.1% napthol blue-black in 45% methanol, 10% acetic acid to assess the
efficiency of transfer. For immune precipitations, lysate was preadsorbed with
protein A-agarose beads (100 μg/ml lysate, Roche, Indianapolis, IN) for 45 min
at 4 °C. The beads were subsequently removed by centrifugation. 100 μg of
preadsorbed lysate was then reacted with 0. 1 μg of primary antibody in a final
adjusted volume of 1 ml (with PBS) for 1 h at 4 °C with rocking. 100 μl protein
A beads (90 mg /ml) were added and the incubation was continued for an
additional hour. Immune complexes were collected by centrifugation, washed
three times with ice-cold PBS, and eluted in sodium dodecyl sulfate (SDS)-
polyacrylamide gel electrophoresis (PAGE) loading buffer for 5 min at 95 °C.
Samples were resolved on 7 or 10% SDS-PAGE gels. Fractionated proteins were
then electrotransferred from the gel to nitrocellulose (Amersham) filters in
Towbin buffer at 200-mA constant current and analyzed by Western blot.
Antibodies used were anti-p53 DO-1 and anti-c-myc (both from Santa Cruz
Biotech, Santa Cruz, CA), anti-Flag, anti-ubiquitin and pan anti-phospho-serine
(from Sigma, St. Louis MO), anti-SV40 large T antigen Ab-1 and anti-p53 PC35
(both from Oncogene, Cambridge, MA), and pan anti-phospho-threonine, anti-
phospho-p53 (ser 392) and anti-phospo-p53 (ser 46) (from Cell Signaling,
Danvers MA). Signal was visualized by the ECL method according to the
manufacturer's protocol (Amersham). For calf intestinal phosphatase (CIP)
experiments, 150 μg of total cell protein lysate was incubated with 20U CIP
(New England Biolabs) for 20 min at 30 °C prior to immune precipitation as
previously described [24].
2.5. Yeast two-hybrid assay
Plasmids pGBKT7-53 and pGADT7-T (Clontech, Palo Alto, CA) were used
as positive controls. Full length p193/CUL7 and p193/CUL7-1152stop were
subcloned into the pGAD7 vector using standard approaches [25]. To quantitate
protein–protein interactions, Saccharomyces cerevisiae Y187 ( MATα, ura3–52,
Fig. 1. Expression of 1152stop protein rendered U2OS cells resistant to MG132-
and etoposide-induced apoptosis. (A) Flow cytometric analysis for cells in early
stages of apoptosis (FITC-Annexin V positive, PI negative; lower right
quadrant); analysis of control (left panel) and MG132-treated (right panel)
U2OS cells were shown. (B) Quantitation of cells at the early stage of apoptosis
in the absence and presence of MG-132 is shown. Asterisk indicated p<0.01 vs.
MG132-treated U2OS, U2OS-nLAC, and MG-63 cells. (C) Quantitation of cells
at the early stage of apoptosis in the absence and presence of etoposide is shown.
Asterisk indicated p<0.01 vs. etoposide-treated U2OS and U2OS-nLAC cells.
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GAL1UAS-GAL1TATA-lacZ, MEL1) was co-transfected with pGBKT7–53 and
with pGADT7-T, pGADT7-p193/CUL7 or pGADT7-1152stop using the
LiOAC method [26]. Transformants were selected on synthesis define medium
(SD) at 30 °C for 6 day s. Four independent colonies for each transfection pair
were individually grown in 50 ml of SD broth at 30 °C with 150 rpm shaking
overnight. Cells were harvested, washed with PBS, and resuspended in Z buffer.
β-galactosidase activity was measured by filter and broth assays per
manufacturer's protocols (Clontech).
2.6. Ablation of endogenous p193/CUL7, Parc, or p53 by RNAi
U2OS cells were maintained in DMEM supplemented with 10% fetal bovine
serum. The RNAi-mediated knockdown of endogenous p193/CUL7, Parc, or
p53 was performed essentially as described previously [18,27] and manufac-
turer's protocol (Dharmacon, Lafayette, CO and Invitrogen). 21-nucleotide
siRNA duplexes with 3′ dTdT overhangs corresponding to p193/CUL7 mRNA
(AACACUGAUCGAGAGGUGCUC) or Parc mRNA (AAGCUUUCCUCGA-
GAUCCAGG) were synthesized (Dharmacon). The Parc mRNA sequence in
the inverted orientation (AAGGACCUAGAGCUCCUUUCG) was used as a
nonspecific RNAi control. Dharmacon p53 SMARTpool was used for RNAi-
mediated p53 ablation. RNAi transfections were performed using Oligofecta-
mine Reagent or Lipofectamine 2000 (Invitrogen). 24 h before transfection,
about 1 million cells were plated on a 10 cm dish. Cells were transfected using
manufacturer's protocol for 1–3 times with 24 h intervals at a concentration of
100 nM.
2.7. Anti-p53 immune cytology
Cells were fixed (acetone/methanol, 1:1, 2 min at room temperature) and
reacted with anti-p53 monoclonal antibody (Ab-1, Oncogene, San Diego CA)
over night at 4 °C, rinsed and then reacted with biotinylated anti-mouse IgG
(Boehringer, Indianapolis IN) for 1 h. Samples were then reacted with
Streptavidin Texas Red (Zymed, San Francisco CA) for 1 h and imaged by
fluorescence microscopy.
2.8. Statistical analyses
The statistical significance was determined by ANOVAwith Tukey multiple
comparisons test for treated cells among groups. P values<0.05 were considered
statistically significant. All results are presented as the mean±SEM (standard
error of the mean).
3. Results
3.1. Antagonization of p193/CUL7 activity rendered U2OS
cells resistant to apoptosis induced by 26S proteasome
inhibition or etoposide treatment
The observations that p193/CUL7 exhibited E3 ubiquitin
ligase activity [16] and that p193/CUL7 transfection induced
apoptosis [7] suggested a potential relationship between p193/
CUL7-mediated ubiquitination and cell death. To test this
possibility, U2OS, U2OS-nLAC (a cell line expressing a
nuclear-localized beta-galactosidase reporter), U2OS-1152stop
(a cell line expressing a c-terminal truncation of mouse p193/
CUL7 with apparent dominant interfering activity) [8], and
MG-63 (a cell line lacking p53) [28] were studied. Cells were
cultured in absence or presence of MG132, a chemical inhibitor
of the 26S proteasome. To monitor apoptosis, cells were
harvested, fixed, and co-stained with FITC-conjugated Annexin
V and propidium iodide. Flow cytometry was used to identify
cells in early stages of apoptosis (i.e., annexin-positive andpropidium iodide negative; Fig. 1A, lower right quadrants).
U2OS, U2OS-nLAC, and MG-63 cells exhibited high levels of
apoptosis following MG132 treatment (Fig. 1B). In contrast,
U2OS-1152stop cells were resistant to MG132-induced apop-
tosis. MG132 treatment resulted in similar levels of ubiquiti-
nated proteins in U2OS-nLAC and U2OS-1152stop cells as
evidenced by Western blots using an anti-ubiquitin antibody
(data not shown). Thus the pro-survival effect that resulted from
1152stop expression was not due simply to global effects of
transgene expression on ubiquitination.
The role of p193/CUL7 in etoposide-induced apoptosis was
also examined. U2OS, U2OS-nLAC, MG-63 and U2OS-
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etoposide and apoptosis was monitored as described above.
Apoptosis was apparent in non-transfected U2OS and U2OS-
nLAC cells after exposure to 25 μM of drug for 8 h (Fig. 1C). In
contrast, apoptosis levels were significantly reduced in both
MG-63 and U2OS-1152stop cells treated with the same dose of
etoposide. At least three trials were performed per group for each
drug treatment (MG132 or etoposide).
3.2. Generation and validation of anti-p193/CUL7 antibodies
In an effort to identify the molecular interactions leading to
apoptosis resistance in cells expressing 1152-stop, monoclonal
antibodies were raised against recombinant protein encoding
p193/CUL7 amino acid residues 805 through 1689. Two
antibodies, AB13 and AB38, were generated. To identify the
epitopes recognized by these antibodies, a nested array of
overlapping 13-amino acid residue synthetic peptides represent-
ing p193/CUL7 amino acid residues 805 through 1689 was
spotted onto a nitrocellulose filter and reacted individually with
AB13 or AB38. Signal was then developed using HRP-Fig. 2. Validation of p193/CUL7 monoclonal antibodies. (A) Identification of the AB
a nitrocellulose filter containing a nested array of overlapping short synthetic pepti
reacted with peptides containing amino acid residues 1660–1677; AB38 reacted with
fetal mouse hearts using AB13 (left panel) and AB38 (middle panel). Right panel s
analysis of U2OS cells following mock transfection, scrambled RNAi transfection,
control. (D)Western blot analysis of U2OS cells following mock transfection, scramb
protein load control. (E) Protein from wild-type (WT) or p193/CUL7 knockout (KO
matched nonspecific antibody, and the resulting immune complex was analyzed byconjugated anti-mouse antibody and ECL (Fig. 2A). These
analyses revealed that AB13 recognized an epitope between
p193/CUL7 amino acid residues 1665 and 1672, while AB38
recognized an epitope between amino acid residues 835 and 842.
Western blot analyses with protein prepared from fetal
mouse hearts revealed that both AB13 and AB38 detected a
protein of approximately 193 kDa (Fig. 2B). AB38 detected a
second protein with a mass of approximately 270 kDa; this
species was also detected in protein prepared from fetal mouse
brain (Fig. 2B). RNA interference (RNAi)/Western blot
analyses were performed to confirm that the 193 kDa protein
detected by the monoclonal antibodies was p193/CUL7. The
193 kDa protein was readily detected by AB38 in mock-
transfected U2OS cells (a human osteosarcoma cell line), and in
U2OS cells transfected with siRNA encoding a scrambled p193/
CUL7 sequence. In contrast, the level of the 193 kDa protein
was markedly decreased in U2OS cells transfected with siRNA
encoding sequences complementary to p193/CUL7 (Fig. 2C).
Similar results were obtained with AB13 (not shown). These
data confirmed that the 193 kDa protein recognized by AB38
and AB13 was p193/CUL7.13 and AB38 epitope binding sites on p193/CUL7. Antibodies were reacted with
des representing p193/CUL7 amino acid residues #805 through #1689. AB13
peptides containing amino acid residues 830–847. (B) Western blot analysis of
hows Western blot analysis of fetal mouse brain using AB38. (C) Western blot
and anti-p193/CUL7 RNAi transfection. The lower panel shows a protein load
led RNAi transfection, and anti-Parc RNAi transfection. The lower panel shows a
) fetal mouse brain was reacted with either AB13, AB38, or an IgG subtype-
Western blotting using AB38 antibody.
Fig. 3. p193/CUL7 interactions in U2OS-nLAC and U2OS-1152stop cells. (A)
Protein from U2OS-nLAC and U2OS-1152stop cells was reacted with either
AB13, anti-p53 DO-1, or IgG subtype-matched nonspecific antibodies, and the
resulting immune complexes were analyzed by Western blotting using AB38
and anti-p53 Ab-7. (B) Beta-galactosidase activity from yeast two-hybrid assays
in cells transfected with the indicated constructs. (C) Protein from U2OS cells
transiently expressing myc-tagged mouse 1152stop molecule (mu1152stop-myc)
or flag-tagged human 1119stop (hu1119stop-flag) was reacted with anti-myc or
anti-flag antibodies. The resulting immune complexes were analyzed by
Western blotting using AB38 and Ab-7 antibodies.
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by AB38, the NCBI database was searched for large proteins
with perfect homology to the AB38 amino acid epitope but
lacking the AB13 epitope. A single candidate was identified, the
UbcH7 associated E3 ubiquitin ligase protein H7-AP1 [29,30],
which was subsequently identified as a cytoplasmic p53 binding
protein and renamed Parc [18]. RNAi/Western blot analyses
were performed to determine if the 270 kDa protein detected by
AB38 was Parc. The 270 kDa protein was readily detected by
AB38 in mock-transfected U2OS cells, and in U2OS cells
transfected with siRNA encoding a scrambled Parc sequence. In
contrast, the level of the 270 kDa protein was markedly
decreased in cells transfected with siRNA complementary to
sequences present in Parc (Fig. 2D). These data confirmed that
the 270 kDa protein recognized by AB38 was Parc.
To determine if the antibodies were suitable for immune
precipitation, protein from fetal mouse brain was reacted with
AB13, and the resulting immune precipitate was analyzed by
Western blot with AB38. Both p193/CUL7 and Parc were
detected in AB13 immune precipitate (Fig. 2E), but not in
control immune precipitate generated with an IgG subtype-
matched nonspecific monoclonal antibody. Given that AB13
failed to recognize Parc in Western blots of whole tissue lysate,
these data suggest that p193/CUL7 and Parc formed a complex.
In support of this, Parc was readily detected in whole tissue
lysate from p193/CUL7-deficient fetal brain, but was not
detected in anti-AB13 immune precipitate (Fig. 2E). These data
confirm the recent observation that p193/CUL7 and Parc form a
complex in vivo [31]. Neither p193/CUL7 nor Parc were
detected in immune precipitate generated with AB38, suggest-
ing that the epitope recognized by this antibody was inaccessible
under non-denaturing conditions.
3.3. 1152stop protein does not alter the endogenous
p193/CUL7 complex in U2OS cells
IP/Western blot analyses were performed to determine if
1152stop binds to and/or alters the composition of endogenous
p193/CUL7 complexes in vivo. In lysate prepared from control
non-transfected U2OS cells, p193/CUL7, Parc, and p53 were
readily detected in total protein samples (Fig. 3A, left panel).
Both p193/CUL7 and Parc were detected by AB38 in immune
precipitate generated with AB13, indicating that p193/CUL7
and Parc bound one another in human cells. In addition, p193/
CUL7 and Parc were also detected by AB38 in immune
precipitate generated with an anti-p53 antibody (DO-1).
Similarly, p53 was detected by anti-p53 antibody AB-7 in
immune precipitate generated with AB13. These data indicated
that p193/CUL7, Parc, and p53 formed either binary or tertiary
complexes.
Similar analysis of lysate prepared from U2OS-1152stop
cells revealed that expression of 1152stop did not alter steady
state levels of endogenous p193/CUL7, Parc, or p53 in total
protein samples (Fig. 3A; right panel; note that due to the
c-terminal truncation, 1152stop protein is recognized by AB38
but not by AB13). p193/CUL7, Parc, and p53 were readily
detected in immune precipitate from U2OS-nLAC and U2OS-1152stop generated with AB13 or with DO-1. In contrast,
1152stop protein was not detected in either AB13 or DO-1
immune precipitate from U2OS-1152stop cells, indicating that
the dominant interfering p193/CUL7 molecule did not bind to
endogenous p193/CUL7 or p53.
The presence of p53 in AB13 immune precipitate from
U2OS cells (Fig. 3A) was inconsistent with the absence of
1152stop/p53 binding in U2OS-1152stop cells. Yeast two-
hybrid assay was used to further examine interactions between
1152stop and p53. The “prey” vector encoded a chimeric
protein containing the GAL4 transactivation domain fused to
1152stop. The “bait” vector encoded a chimeric protein
containing mouse p53 fused to the GAL4 DNA binding
domain. Transfection of the prey and bait vectors alone or in
combination into yeast carrying a GAL4-dependent beta-
galactosidase reporter gene resulted in similar albeit very low
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not interact (Fig. 3B). As a positive control, prey vector that
encoded a chimeric protein comprised of the GAL4 transactiva-
tion domain fused to T-Antigen was co-transfected with the p53/
GAL4 bait vector into the reporter yeast strain. This co-
transfection resulted in robust beta-galactosidase activity (Fig.
3B). Additional experiments demonstrated that full-length
mouse p193/CUL7 also did not interact with p53 in this assay
system (Fig. 3B).
To determine if there might be species-specific differences in
p193/CUL7 binding partners, U2OS cells were transiently
transfected with a construct expressing a myc-tagged mouse
p193/CUL7 1152stop molecule (designated mu1152stop-myc)
or with a construct expressing a flag-tagged human p193/CUL7
cDNA with a stop codon inserted at amino acid residue 1120
(designated hu1119stop-flag). IP/Western analyses revealed that
p53 was not present in anti-myc immune precipitate from cells
transiently expressing mu1152stop-myc, confirming that this
fragment of mouse p193/CUL7 did not bind to p53 (Fig. 3C). In
contrast, p53 was readily detected in anti-flag immune
precipitate from cells transiently expressing hu1119stop-flag,
indicating that the analogous C-terminal truncation molecule of
human p193/CUL7 did bind to p53. Thus human, but not mouse,
p193/CUL7 binds to p53. Interestingly, the absence of Parc in
immune complexes generated with truncated, epitope-tagged
human and mouse p193/CUL7 molecules indicated that the c-
terminal region was required for binding to Parc (compare IPFig. 4. Cytoplasmic sequestration of p53 was not dependent upon interactions with p1
N-AS cells. (B) Protein from U2OS or SK-N-AS was reacted with either AB13, an
immune complexes were analyzed by Western blotting using AB38 and anti-p53 Ab-
flag was reacted with anti-flag, DO-1, or an IgG subtype-matched control antibody,
AB38 and Ab-7 antibodies. (D) Protein from U2OS cells incubated in the absence or p
an IgG subtype-matched control antibody, and the resulting immune complexes
interpretation of the references to colour in this figure legend, the reader is referredcomplexes with the truncated p193/CUL7 molecules in Panel C
to those with the full-length molecules in Panel A).
3.4. Binding to p193/CUL7/Parc complex is not required for
cytoplasmic localization of p53
Although previous studies demonstrated co-localization of
Parc and p53 in the cytoplasm of SK-N-AS neuroblastoma cells
[18], their physical interaction was not demonstrated in that
study. Immune cytology analyses confirmed that p53 was
localized in the cytoplasm in both U2OS and SK-N-AS cells
(Fig. 4A). Moreover, Western blot analysis of total protein
samples revealed that U2OS and SK-N-AS cells expressed
similar levels of p193/CUL7, Parc, and p53 (Fig. 4B). In U2OS
cells, p193/CUL7, Parc, and p53 were present in immune
precipitate generated using either AB13 or DO-1. In contrast,
p193/CUL7 and Parc were not present in DO-1 immune
precipitate generated from SK-N-AS cells, and p53 was not
present in AB13 immune precipitate (Fig. 4B). Since Parc and
p53 do not bind one another in SK-N-AS cells, interactions
between these two proteins cannot explain the observed
cytoplasmic p53 localization.
Since SK-N-AS cells express wild type p53, additional
experiments were performed to determine if the absence of p53/
p193 binding was due to acquired mutations in the endogenous
p193. SK-N-AS cells were transiently transfected with
hu1119stop-flag, which avidly bound p53 in U2OS cells (see93/CUL7 or Parc. (A) Anti-p53 immune cytology (red signal) of U2OS and SK-
ti-p53 DO-1, or IgG subtype-matched nonspecific antibodies, and the resulting
7. (C) Protein prepared from SK-N-AS cells transiently expressing hu1119stop-
and the resulting immune complexes were analyzed by Western blotting using
resence of calf intestinal phosphatase (CIP) was reacted with anti-flag, DO-1, or
were analyzed by Western blotting using AB38 and Ab-7 antibodies. (For
to the web version of this article.)
Fig. 5. (A) p53 in anti-p93/CUL7 immune complex exhibits phospho-threonine
immune reactivity. Protein from U2OS cells was reacted with either AB13, anti-
p53 DO-1, or IgG subtype-matched nonspecific antibodies, and the resulting
immune complexes were analyzed by Western blotting using AB38, pan anti-
phospho-threonine or pan anti-phospho-serine (upper three panels), or using anti-
p53 Ab-7, pan anti-phospho-threonine, or anti-p53-phospho-serine392 antibodies
(lower three panels). (B) Murine p193/CUL7 does not bind to Bcl-xL or Bax.
Protein from NIH-3T3 cells was reacted with either AB38, AB13, anti-Bcl-xL or
anti-Bax antibody, and the resulting immune complexes were analyzed by
Western blotting using AB38, anti-Bcl-xL and anti-Bax antibody.
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in anti-flag immune complex, and that hu1119stop-flag was not
present in anti-p53 DO-1 immune complex (Fig. 4C). To
determine if post-translational modification affected p193/
CUL7 and p53 binding, IP/Western experiments were per-
formed with control and calf intestinal phosphatase (CIP)-
treated protein from U2OS cells. In the absence of CIP
treatment, p53 was readily detected in immune complex
generated with AB13, while p193/CUL7 and Parc were readily
detected in DO-1 immune complex (Fig. 4D). CIP treatment
resulted in the loss of p53 in immune complex generated with
AB13, and the loss of p193/CUL7 and Parc in immune complex
generated with DO-1. These data suggested that post-transla-
tional modification was required for p53 to bind to p193/CUL7
and/or Parc.
To determine what phosphorylation events might give rise to
p53 binding, lysate from U2OS cells was immune precipitated
with AB13, DO-1, or control IgG, and the resulting immune
precipitate was analyzed by Western blot. No p193/CUL7 or
Parc phosphorylation was detected in Western blots using pan
anti-phospho-threonine or pan anti-phospho-serine antibodies
(within the limits of the sensitivity of the assay, see Fig. 5A).
However, p53 phosphorylation was detected with a pan anti-
phospho-threonine antibody, as well as with an antibody which
specifically recognizes p53 when phosphorylated at serine
residue 392 (Fig. 5A). The presence of phospho-p53 immune
reactivity in the AB13 immune complex suggests that this
species of p53 is responsible for binding activity. Similar IP-
Western analyses with an antibody which specifically recog-
nizes p53 when phosphorylated at serine residue 46 did not give
rise to signal (not shown).
Finally, additional IP/Western blot analyses were performed
to determine if p193/CUL7 binds to Bcl-xL and/or Bax. NIH-
3T3 cells were used as they are devoid of Parc, thus making
identification of p193/CUL7 binding proteins less ambiguous.
p193/CUL7, Bcl-xL, and Bax were readily detected in total
protein samples (Fig. 5B). Neither Bcl-xL nor Bax was present
in immune complex generated with anti-p193/CUL7 antibody
AB13. Similarly, p193/CUL7 was not present in anti-Bcl-xL or
anti-Bax immune precipitate. Thus, p193/CUL7 does not bind
to endogenous Bcl-xL or Bax. As a positive control, interaction
between Bax and Bcl-xL was readily detected.
4. Discussion
The data presented here demonstrated that expression of the
1152stop protein inhibited MG132- and etoposide-induced
apoptosis. The mechanism by which 1152stop inhibits apoptosis
is not clear. In the case of MG132 treatment, the inability of
1152stop to bind to p53, and the presence of high levels of
apoptosis in p53-null, indicated that apoptosis resistance
occurred via a p53-independent pathway. This notion was
supported by previous observations indicating that MG132-
induced apoptosis was independent of the activities of p53 and
p21 [18,20,29]. Given that MG132 inhibits the 26S proteasome,
it is unlikely that 1152stop-induced anti-apoptotic activity
resulted from simple inhibition of p193/CUL7 E3 ligase activity.In this regard it is of interest to note that p193/CUL7 was shown
to induce apoptosis in NIH-3T3 cells [7]. This pro-apoptotic
activity was dependent upon the presence of an intact BH3motif
in the c-terminus, and was antagonized by co-expression of Bcl-
xL. Indeed, another E3 ligase with BH3-dependent pro-
apoptosis activity has recently been identified [32]. Expression
of 1152stopmight have interfered with activation of endogenous
p193/CUL7 pro-apoptotic activity, thus rendering the cells
resistant to MG132. However, IP/Western blot analyses failed to
demonstrate a direct interaction between p193/CUL7 and Bcl-
xL or Bax.
1152stop also rendered U2OS cells resistant to etoposide-
induced apoptosis. Etoposide (a commonly used chemother-
apeutic agent) was previously shown to induce apoptosis largely
365J.D. Dowell et al. / Biochimica et Biophysica Acta 1773 (2007) 358–366via a p53-dependent pathway [33–35]. However, expression of
1152stop did not affect levels of p53 in the absence (Fig. 3A) or
presence (J. Dowell, unpublished observation) of etoposide.
This, plus the observation that 1152stop did not bind to p53,
suggested that 1152stop-mediated resistance to etoposide-
induced apoptosis also resulted via a p53-independent mechan-
ism. Previous studies revealed that etoposide treatment resulted
in G2 cell cycle arrest, which in turn induced apoptosis [36,37].
If G2-M transit required the presence of a protein targeted for
ubiquitination by p193/CUL7, and if etoposide treatment
lowered the effective concentration of that protein, it is possible
that expression of 1152stop (with concomitant antagonization of
endogenous p193/CUL7 activity) could restore levels to an
effective concentration. The etoposide-induced G2 cell cycle
block would thus be relaxed, which in turn could reduce the level
of drug-induced apoptosis. In support of this scenario, expres-
sion of either 1152stop or p193/CUL7 anti-sense enhanced cell
growth in an NIH-3T3 colony growth assay [8]. Similarly,
targeted expression of 1152stop in the myocardium of transgenic
mice was sufficient to relax the cell cycle checkpoints that
otherwise prevented cardiomyocyte cell cycle reactivation
following cardiac injury [38]. Definitive testing of the hypoth-
esis however will require identification of the molecular targets
of the mouse p193/CUL7 in U2OS cells.
The observation that p193/CUL7 formed a complex with
Parc and p53 confirmed and extended recent observations from
Skaar and colleagues [31]. These authors demonstrated the
presence p193/CUL7–Parc complex in both U2OS cells and
mouse embryonic fibroblasts (MEFs). The inability of mouse
p193/CUL7 to bind to p53 (Fig. 3B, C) suggested that the
presence of low levels of p53 in anti-Parc immune complex [31]
resulted from direct interactions between p53 and Parc. Down-
regulation of p193/CUL7 expression via RNAi treatment (Fig.
2C) or gene targeting (Fig. 2E) did not affect steady state levels
of Parc. This is in contrast to the results of Skaar and colleagues,
where targeting of the p193/CUL7 gene resulted in a dramatic
reduction in Parc levels [31]. Given the close proximity of the
p193/CUL7 and Parc genes (only 186 kb apart), it is possible
that the p193/CUL7 targeting event(s) may have impacted
expression of Parc. Although the significance of the binding
between p193/CUL7 and Parc is presently not clear, the
presence of both proteins in large (i.e., >1 mD) complexes [18]
raised the possibility that such protein–protein interactions
might expand the spectrum of potential targets for p193/CUL7-
mediated ubiquitination.
Gu and colleagues recently suggested that Parc functioned as
an anchor protein that tethered p53 to the cytoplasm [18]. The
observation that Parc and p53 bind to one another in U2OS
cells, and that p53 is sequestered to the cytoplasm of those cells
(Fig. 4), would tend to support this view. However, the absence
of co-immune precipitation of Parc with p53 in SK-N-AS cells
indicates that direct binding of these two proteins is not required
for sequestration of p53 to the cytoplasm. This view is further
supported by the inability of truncated human p193/CUL71119-
stop-flag to bind to p53 following transfection into SK-N-AS
cells (the observed binding of p53 to truncated human p193/
CUL71119stop-flag in U2OS cells provides a compellingpositive control). Although p53 binding to p193/CUL7–Parc
complex is sensitive to phosphorylation status, it is not clear if
post-translational modification impacted upon sub-cellular
localization in other cell types.
In summary, expression of 1152stop, a dominant interfering
version of mouse p193/CUL7, conferred resistance to MG132-
and etoposide-induced apoptosis in U2OS cells. The inability of
the 1152stop protein to bind to p53, and the observation that
1152stop expression did not alter the endogenous p193/CUL7–
Parc–p53 complex, suggested that resistance to apoptosis
occurred via a p53-independent pathway. Cytoplasmic localiza-
tion of p53 in SK-N-AS cells was not dependent upon binding
to Parc and/or p193/CUL7. Finally, binding of p53 to the p193/
CUL7–Parc complex appeared to be dependent upon the
phosphorylation status of at least one of the proteins. These data
support a role for p193/CUL7 in the regulation of apoptosis
independently of p53 activity.
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